CN109432165A - A kind of anaesthetic and preparation method thereof for treating asthma - Google Patents
A kind of anaesthetic and preparation method thereof for treating asthma Download PDFInfo
- Publication number
- CN109432165A CN109432165A CN201811575416.0A CN201811575416A CN109432165A CN 109432165 A CN109432165 A CN 109432165A CN 201811575416 A CN201811575416 A CN 201811575416A CN 109432165 A CN109432165 A CN 109432165A
- Authority
- CN
- China
- Prior art keywords
- parts
- anaesthetic
- preparation
- asthma
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 104
- 229940079593 drug Drugs 0.000 claims abstract description 51
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims abstract description 48
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 46
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 46
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 claims abstract description 40
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000126 substance Substances 0.000 claims abstract description 38
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 claims abstract description 22
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000006187 pill Substances 0.000 claims abstract description 22
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 claims abstract description 20
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims abstract description 20
- PXOYOCNNSUAQNS-UHFFFAOYSA-N alantolactone Natural products C1C2OC(=O)C(=C)C2C=C2C(C)CCCC21C PXOYOCNNSUAQNS-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000008777 kaempferol Nutrition 0.000 claims abstract description 20
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000010231 banlangen Substances 0.000 claims abstract description 16
- 235000017847 Anchusa officinalis Nutrition 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 241000271309 Aquilaria crassna Species 0.000 claims description 45
- 239000000341 volatile oil Substances 0.000 claims description 31
- 239000002023 wood Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 244000272264 Saussurea lappa Species 0.000 claims description 24
- 235000006784 Saussurea lappa Nutrition 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 24
- 244000223014 Syzygium aromaticum Species 0.000 claims description 23
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 23
- 244000138993 panchioli Species 0.000 claims description 23
- 235000011517 Terminalia chebula Nutrition 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 17
- 241000253121 Inula britannica Species 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 15
- 241001092389 Sorbaria Species 0.000 claims description 14
- 244000242323 Anchusa officinalis Species 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 12
- 206010047700 Vomiting Diseases 0.000 claims description 12
- 230000008673 vomiting Effects 0.000 claims description 12
- 244000116484 Inula helenium Species 0.000 claims description 11
- 235000013422 Kaempferia rotunda Nutrition 0.000 claims description 11
- 241000219071 Malvaceae Species 0.000 claims description 11
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 239000001702 nutmeg Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 235000002598 Inula helenium Nutrition 0.000 claims description 10
- 244000062250 Kaempferia rotunda Species 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 239000008236 heating water Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 244000111489 Gardenia augusta Species 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 230000000202 analgesic effect Effects 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 244000270834 Myristica fragrans Species 0.000 claims description 2
- 244000277583 Terminalia catappa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 64
- 231100000331 toxic Toxicity 0.000 abstract description 9
- 230000002588 toxic effect Effects 0.000 abstract description 9
- 230000010534 mechanism of action Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 241000734282 Helminthotheca echioides Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- -1 mixes Substances 0.000 description 25
- 241000001522 Terminalia chebula Species 0.000 description 19
- 239000002075 main ingredient Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- 229930182478 glucoside Natural products 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 241000498779 Myristica Species 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 240000001972 Gardenia jasminoides Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 150000008131 glucosides Chemical class 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 239000008845 cholagoga Substances 0.000 description 5
- 229940124571 cholagogue Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000002110 toxicologic effect Effects 0.000 description 5
- 231100000027 toxicology Toxicity 0.000 description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 4
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 4
- 241000208838 Asteraceae Species 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 4
- 244000062241 Kaempferia galanga Species 0.000 description 4
- QSPOERJDZBVCJH-UHFFFAOYSA-N Kutkin Natural products COc1cc(ccc1OC2OC(CO)C(O)C(O)C2O)C(O)(OC)C(=O)OC=Cc3ccccc3 QSPOERJDZBVCJH-UHFFFAOYSA-N 0.000 description 4
- XSIQHIDJSCQWBB-QHJBZRDQSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-methoxy-4-[(E)-3-phenylprop-2-enoyl]oxybenzoate dihydrate Chemical compound O.O.COc1cc(ccc1OC(=O)\C=C\c1ccccc1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XSIQHIDJSCQWBB-QHJBZRDQSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000011262 co‐therapy Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 4
- IGGUPRCHHJZPBS-UHFFFAOYSA-N nonacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC IGGUPRCHHJZPBS-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 3
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001483116 Neopicrorhiza scrophulariiflora Species 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229930014456 matrine Natural products 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 229940007046 shigella dysenteriae Drugs 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
- WSGPLSDARZNMCW-FCVLBCLDSA-N 6beta-Hydroxygeniposide Natural products O([C@@H]1OC=C([C@@H]2[C@H]1C(=C[C@@H]2O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WSGPLSDARZNMCW-FCVLBCLDSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 235000003301 Ceiba pentandra Nutrition 0.000 description 2
- 244000146553 Ceiba pentandra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 description 2
- VKWWRUZYBNTDHM-AXECJBQYSA-N Deacetylasperulosidic acid Natural products OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O VKWWRUZYBNTDHM-AXECJBQYSA-N 0.000 description 2
- WSGPLSDARZNMCW-UHFFFAOYSA-N Deacetylasperulosidsaeure-methylester Natural products OC1C=C(CO)C2C1C(C(=O)OC)=COC2OC1OC(CO)C(O)C(O)C1O WSGPLSDARZNMCW-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- FYZYXYLPBWLLGI-AUOPOVQUSA-N Genipin 1-beta-gentiobioside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FYZYXYLPBWLLGI-AUOPOVQUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 241000395033 Kaempferia Species 0.000 description 2
- 235000013421 Kaempferia galanga Nutrition 0.000 description 2
- VLCHQFXSBHIBRV-KNNWKXJLSA-N Mussaenosidic acid Natural products O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2 VLCHQFXSBHIBRV-KNNWKXJLSA-N 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 2
- 241000123069 Ocyurus chrysurus Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- WSGPLSDARZNMCW-LPGRTNKPSA-N Scandoside methyl ester Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=C[C@H]2O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WSGPLSDARZNMCW-LPGRTNKPSA-N 0.000 description 2
- YSIFYNVXJOGADM-KDYWOABDSA-N Shanzhiside Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@H](O)C[C@@]2(O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YSIFYNVXJOGADM-KDYWOABDSA-N 0.000 description 2
- PVPIPGMAEAJMTH-UHFFFAOYSA-N Shanzhiside Natural products OCC1OC(OC2OC=C(C3C(O)CC(O)C23)C(=O)O)C(O)C(O)C1O PVPIPGMAEAJMTH-UHFFFAOYSA-N 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 244000218979 Spondias axillaris Species 0.000 description 2
- 235000014116 Spondias axillaris Nutrition 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 description 2
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 2
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 2
- PNHQFFOWCUDBPX-UHFFFAOYSA-N methyl 7-formylcyclopenta[c]pyran-4-carboxylate Chemical compound COC(=O)C1=COC=C2C(C=O)=CC=C12 PNHQFFOWCUDBPX-UHFFFAOYSA-N 0.000 description 2
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- BBFYUPYFXSSMNV-HMGRVEAOSA-N quercetin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-HMGRVEAOSA-N 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 2
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 2
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 2
- UFCLZKMFXSILNL-BBLPPJRLSA-N (-) 4,5-dicaffeoylquinic acid Natural products OC=1C=C(C=CC=1O)C=CC(=O)O[C@@H]1C[C@@](C[C@H]([C@H]1OC(C=CC1=CC(=C(C=C1)O)O)=O)O)(C(=O)O)O UFCLZKMFXSILNL-BBLPPJRLSA-N 0.000 description 1
- ZVXWFPTVHBWJOU-AWQYILTISA-N (1s,4as,5r,7as)-5-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C(C(O)=O)=CO1 ZVXWFPTVHBWJOU-AWQYILTISA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- SWMBOMMGMHMOHE-KZXKDKCNSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SWMBOMMGMHMOHE-KZXKDKCNSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- YGVHOSGNOYKRIH-UHFFFAOYSA-N 1,3,6-tri-O-galloyl-2,4-O-chebuloyl-beta-D-glucopyranose Natural products O1C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(C2OC(=O)C=3C=C(O)C(O)=C(O)C=3)OC(=O)C(C3=4)=CC(O)=C(O)C=4OC(=O)C(O)C3C(CC(O)=O)C(=O)OC2C1COC(=O)C1=CC(O)=C(O)C(O)=C1 YGVHOSGNOYKRIH-UHFFFAOYSA-N 0.000 description 1
- LOXQKSBAJJTUOX-UHFFFAOYSA-N 10-Acetylgeniposid Natural products C1C=C(COC(C)=O)C2C1C(C(=O)OC)=COC2OC1OC(CO)C(O)C(O)C1O LOXQKSBAJJTUOX-UHFFFAOYSA-N 0.000 description 1
- UFCLZKMFXSILNL-GCBRTHAASA-N 102851-07-0 Natural products OC=1C=C(C=CC=1O)C=CC(=O)O[C@@H]1C[C@](C[C@H]([C@@H]1OC(C=CC1=CC(=C(C=C1)O)O)=O)O)(C(=O)O)O UFCLZKMFXSILNL-GCBRTHAASA-N 0.000 description 1
- YIEASZQRMGWKDX-UHFFFAOYSA-N 3,4-Di-O-caffeoylquinic acid Natural products OC1CC(O)(CC(OC(=O)C=Cc2ccc(O)c(O)c2)C1OC(=O)C=Cc3cccc(O)c3O)C(=O)O YIEASZQRMGWKDX-UHFFFAOYSA-N 0.000 description 1
- UFCLZKMFXSILNL-PSEXTPKNSA-N 3,4-di-O-Caffeoylquinic acid Natural products O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 description 1
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 description 1
- OOGPWQHGQYUIAW-UHFFFAOYSA-N 3,5-di-O-caffeoyl-4-O-(3-hydroxy-3-methyl)glutaroylquinic acid Natural products OC(=O)CC(O)(C)CC(=O)OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 OOGPWQHGQYUIAW-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- BEDSGEULUAVXQH-UHFFFAOYSA-N 3-O-caffeoyl-4-O-sinapoylquinic acid Natural products COC1=C(O)C(OC)=CC(C=CC(=O)OC2C(CC(O)(CC2O)C(O)=O)OC(=O)C=CC=2C=C(O)C(O)=CC=2)=C1 BEDSGEULUAVXQH-UHFFFAOYSA-N 0.000 description 1
- OLNCJMCWTONFER-LFHLZQBKSA-N 3-phenyl-1-[(2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]prop-2-en-1-one Chemical compound C(C=CC1=CC=CC=C1)(=O)[C@@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO OLNCJMCWTONFER-LFHLZQBKSA-N 0.000 description 1
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- YGVHOSGNOYKRIH-FJPMMHPYSA-N Chebulinic acid Chemical group C([C@@H]1[C@H]2OC(=O)[C@@H](CC(O)=O)[C@@H]3[C@@H](C(OC=4C(O)=C(O)C=C(C3=4)C(=O)O[C@@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O1)[C@H]2OC(=O)C=1C=C(O)C(O)=C(O)C=1)=O)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 YGVHOSGNOYKRIH-FJPMMHPYSA-N 0.000 description 1
- MHDANAFDVQLLPY-UHFFFAOYSA-N Chebulinic acid Natural products OC(C1C(CC(=O)O)C(=O)OC2C(COC(=O)c3cc(O)c(O)c(O)c3)OC(OC(=O)c4cc(O)c(O)c(O)c4)C(OC(=O)c5cc(O)c(O)c(O)c15)C2OC(=O)c6cc(O)c(O)c(O)c6)C(=O)O MHDANAFDVQLLPY-UHFFFAOYSA-N 0.000 description 1
- 229920000585 Chebulinic acid Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000221032 Combretaceae Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- JSKCJJNYSGWZDU-RQJSCMEKSA-N Gardoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(=C)[C@@H](O)C[C@@H]2C(C(O)=O)=CO1 JSKCJJNYSGWZDU-RQJSCMEKSA-N 0.000 description 1
- JSKCJJNYSGWZDU-PKPQBBKFSA-N Gardoside Natural products O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(=C)[C@@H](O)C2 JSKCJJNYSGWZDU-PKPQBBKFSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- ZJDOESGVOWAULF-OGJQONSISA-N Geniposidic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=CC[C@@H]2C(C(O)=O)=CO1 ZJDOESGVOWAULF-OGJQONSISA-N 0.000 description 1
- VYAALAFRWREWLA-BVTMAQQCSA-N Geniposidic acid Natural products CCC1=CC[C@H]2[C@@H]1[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C2C(=O)O VYAALAFRWREWLA-BVTMAQQCSA-N 0.000 description 1
- ZJDOESGVOWAULF-UHFFFAOYSA-N Geniposidinsaeure Natural products OC1C(O)C(O)C(CO)OC1OC1C2C(CO)=CCC2C(C(O)=O)=CO1 ZJDOESGVOWAULF-UHFFFAOYSA-N 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001081833 Myristicaceae Species 0.000 description 1
- UFCLZKMFXSILNL-UHFFFAOYSA-N NSC 649410 Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC1C(O)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019116 Paederia foetida Nutrition 0.000 description 1
- 240000008379 Paederia scandens Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- WMHJCSAICLADIN-MVVLZTAMSA-N Picrocrocin Natural products O=CC=1C(C)(C)C[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)CC=1C WMHJCSAICLADIN-MVVLZTAMSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- IDTDRZPBDLMCLB-HSOQPIRZSA-N Quercetagitrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC2=C1C(=O)C(O)=C(C=1C=C(O)C(O)=CC=1)O2 IDTDRZPBDLMCLB-HSOQPIRZSA-N 0.000 description 1
- IDTDRZPBDLMCLB-UHFFFAOYSA-N Quercetagitrin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C(O)=C(C=1C=C(O)C(O)=CC=1)O2 IDTDRZPBDLMCLB-UHFFFAOYSA-N 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000007234 Rhodomyrtus tomentosa Nutrition 0.000 description 1
- 240000007994 Rhodomyrtus tomentosa Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000133134 Saussurea Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 241000217239 Schizotrypanum Species 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241001145009 Sophora alopecuroides Species 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000566916 Tomentella Species 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- NZCULBURCGAPSF-UHFFFAOYSA-N UNPD19956 Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C NZCULBURCGAPSF-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- XZGPUOQGERGURE-LUVHZPKESA-N [(2r,3s,4s,5r,6s)-6-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (e)-3-phenylprop-2-enoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C[C@H]2[C@H](O)[C@@H]3O[C@@]3([C@@H]12)CO)OC(=O)\C=C\C1=CC=CC=C1 XZGPUOQGERGURE-LUVHZPKESA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- HMKKIXGYKWDQSV-KAMYIIQDSA-N alpha-Amylcinnamaldehyde Chemical compound CCCCC\C(C=O)=C\C1=CC=CC=C1 HMKKIXGYKWDQSV-KAMYIIQDSA-N 0.000 description 1
- TUFPZQHDPZYIEX-UHFFFAOYSA-N alpha-Santonin Natural products C1CC2(C)C=CC(=O)C=C2C2C1C(C)C(=O)O2 TUFPZQHDPZYIEX-UHFFFAOYSA-N 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- XJHDMGJURBVLLE-BOCCBSBMSA-N alpha-santonin Chemical compound C([C@]1(C)CC2)=CC(=O)C(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 XJHDMGJURBVLLE-BOCCBSBMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229930188866 apocynin Natural products 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 description 1
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical group CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- UGIVASYMZSZAMP-UHFFFAOYSA-N chebulagic acid Natural products OC1C2c3c(OC1=O)c(O)c(O)cc3C(=O)OC4C(OC(=O)c5cc(O)c(O)c(O)c5)OC6COC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OC4C6OC(=O)C2(O)C(=O)O UGIVASYMZSZAMP-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- OXNHRKGZZFWUQZ-UHFFFAOYSA-N crocetin dimethyl ester Natural products COC(=O)C(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C(=O)OC OXNHRKGZZFWUQZ-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- NETSQGRTUNRXEO-XUXIUFHCSA-N dehydrocostus lactone Chemical compound C([C@H]1C(=C)C(=O)O[C@@H]11)CC(=C)[C@H]2[C@@H]1C(=C)CC2 NETSQGRTUNRXEO-XUXIUFHCSA-N 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- OXNHRKGZZFWUQZ-QORFUXSJSA-N gamma-Crocetin Chemical compound COC(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)OC OXNHRKGZZFWUQZ-QORFUXSJSA-N 0.000 description 1
- WSKNCDIGADDYAP-FLVHOVDBSA-N genipin 1-O-beta-D-isomaltoside Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H]4C(=CC[C@]14C)CO WSKNCDIGADDYAP-FLVHOVDBSA-N 0.000 description 1
- 150000002275 gentiobioses Chemical class 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- SCIGYBYAZUFDLA-YRWPAIAPSA-N globularin Natural products OC[C@H]1O[C@@H](O[C@@H]2OC=C[C@H]3[C@H](O)[C@@H]4O[C@]4(COC(=O)C=Cc5ccccc5)[C@@H]23)[C@H](O)[C@@H](O)[C@@H]1O SCIGYBYAZUFDLA-YRWPAIAPSA-N 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CVUANYCQTOGILD-QVHKTLOISA-N isoalantolactone Chemical compound C1CCC(=C)[C@@H]2C[C@@H]3C(=C)C(=O)O[C@@H]3C[C@]21C CVUANYCQTOGILD-QVHKTLOISA-N 0.000 description 1
- CVUANYCQTOGILD-UHFFFAOYSA-N isoalantolactone Natural products C1CCC(=C)C2CC3C(=C)C(=O)OC3CC21C CVUANYCQTOGILD-UHFFFAOYSA-N 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 description 1
- IPWBXORAIBJDDQ-UHFFFAOYSA-N methyl 2-hexyl-3-oxocyclopentane-1-carboxylate Chemical compound CCCCCCC1C(C(=O)OC)CCC1=O IPWBXORAIBJDDQ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- WMHJCSAICLADIN-WYWSWGBSSA-N picrocrocin Chemical compound C1C(C)=C(C=O)C(C)(C)C[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WMHJCSAICLADIN-WYWSWGBSSA-N 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940074353 santonin Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- NUPTUAXNMUIMFS-MIHIQLSESA-N terchebin Chemical compound C([C@@H]1[C@H]2OC(=O)C=3[C@H]4C5=C(C(O[C@@H]([C@H](OC(=O)C=6C=C(O)C(O)=C(O)C=6)O1)[C@H]2OC(=O)C=1C=C(O)C(O)=C(O)C=1)=O)C=C(C(=C5OC4(O)C(O)(O)C(=O)C=3)O)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 NUPTUAXNMUIMFS-MIHIQLSESA-N 0.000 description 1
- ULYXEEKCDUUGNM-UHFFFAOYSA-N terchebin Natural products Oc1cc(cc(O)c1O)C(=O)OCC2OC(OC(=O)c3cc(O)c(O)c(O)c3)C4OC(=O)C5CC(=O)C(=O)C(=O)C5c6c(O)c(O)c(O)cc6C(=O)OC2C4OC(=O)c7cc(O)c(O)c(O)c7 ULYXEEKCDUUGNM-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000000654 trypanocidal effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of drug and preparation method, i.e., a kind of anaesthetic and preparation method thereof for treating asthma.It is characterized by: the anaesthetic includes the bulk pharmaceutical chemicals of following parts by weight: 10-15 parts of oxtongue, 0.5-0.7 part of Banlangen, 0.06-0.08 part of alantolactone, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin, 0.05-0.07 part of Kaempferol.Preparation method, it is characterised in that: the bulk pharmaceutical chemicals be crushed into 80 meshes, mix, powder or water-bindered pill agent or tablet is made.Beneficial effect is: providing a kind of pair of asthma with significant curative effect, and the mechanism of action is clear, active component is clear, taking dose is small, it is quickly effective, it has no toxic side effect, convenient for the anaesthetic for the treatment asthma taken, and the preparation method that the crude drug for breaking traditional mongolian medicine crushes, using modern science and technology, have developed a kind of environmentally protective, preparation method is simple, the preparation method to match with above-mentioned anaesthetic has played the maximum effect of above-mentioned anaesthetic.
Description
Technical field
The present invention relates to a kind of drug and preparation method, i.e., a kind of anaesthetic and preparation method thereof for treating asthma.
Background technique
Asthma is the abbreviation of bronchial asthma.Bronchial asthma is that (such as eosinophil, hypertrophy are thin by various kinds of cell
Born of the same parents, T lymphocyte, neutrophil leucocyte, human airway epithelial cells etc.) and cellular component participation chronic airway inflammation illness.It is this
Chronic inflammation leads to the generation of airway hyperreactivity, generally occurs within reversible airflow limitation changeable extensively, and cause to send out repeatedly
Make wheeze, be out of breath, the symptoms such as uncomfortable in chest or cough, often in night and (or) morning breaking-out, most of patients voluntarily can alleviate or pass through
Treatment is alleviated.
Mongolian medicine thinks that for the disease mainly due to three unbalance, Xi La and Ba Dagan Xiang Bohou acts on airway walls, then
Department's life is conspicuous according to dysfunction, leads to the disease.Be mainly shown as repeatability wheeze, be uncomfortable in chest, shortness of breath, cough, expectoration, expiratory dyspnea,
Whistling sound in the throat etc..The common anaesthetic of Mongolian medicine has the equal drugs of Ah loud, high-pitched sound day -8, Ba Te -7, E and wood -8, equal to asthma
With good therapeutic effect, as classical Mongolian medicine's proved recipe, although the treatment works well, due to lacking modern technologies hand
Section, the mechanism of action of drug is relatively fuzzyyer, and effective component is mostly uncertain, and is all made of traditional preparation method, is mixed into effective component
A large amount of invalid components, so that taking dose is big, slowly effective, toxic side effect is strong, and the equal flavour of a drug of anaesthetic are big, limits opening for anaesthetic
Hair utilizes.
Summary of the invention
The object of the present invention is to provide a kind of pair of asthma to have significant curative effect, and the mechanism of action is clear, and active component is clear,
Taking dose is small, quickly effective, has no toxic side effect, convenient for the preparation method of the anaesthetic for the treatment of asthma and this drug taken.
Above-mentioned purpose is realized by the following technical solutions: a kind of anaesthetic for treating asthma, it is characterised in that: the anaesthetic
Bulk pharmaceutical chemicals including following parts by weight: 10-15 parts of oxtongue, 0.5-0.7 part of Banlangen, alantolactone 0.06-0.08
Part, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin, 0.05-0.07 part of Kaempferol.
The raw material medicaments in part by weight is added: 5-7 parts of fructus choerospondiatis, 5-7 parts of falsespiraea tree bark, and 9-11 parts of Inula britannica chinensis, myrobalan
5-7 parts.
The raw material medicaments in part by weight is added: 5-7 parts of Radix picrorrhizae, 5-7 parts of common bombax flower, and 9-11 parts of nutmeg, Strychnos nux-vomica
9-11 parts, 6-8 parts of Fructus meliae toosendan of sub (system).
The raw material medicaments in part by weight is added: 5-7 parts of agalloch eaglewood, 12-13 parts of dalbergia wood, and 12-13 parts of mountain agalloch eaglewood, costus root
9-11 parts, 9-11 parts of cloves.
Described 0.5-0.7 part of Banlangen is substituted by 5-7 parts of kuh-seng, and 0.06-0.08 part of alantolactone by building
Fragrant 5-6 parts of substitutions, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin substituted by 38-42 parts of cape jasmines, Kaempferol 0.05-
0.07 part is substituted by 5-7 parts of kaempferia galamgas.
A kind of preparation method of anaesthetic that treating asthma, it is characterised in that: the bulk pharmaceutical chemicals be crushed into 80 meshes, mixed
It is even, powder or water-bindered pill agent or tablet is made.
A kind of preparation method of anaesthetic that treating asthma, it is characterised in that: by the agalloch eaglewood in bulk pharmaceutical chemicals, dalbergia wood, mountain agalloch eaglewood,
Costus root, cloves are ground into coarse powder, add distilled water, impregnate 30min, are placed in volatile oil extractor, add water, past medicine
Material liquid level 3-4cm, heating water bath collect the volatile oil that above-mentioned raw materials medicine extracts, spare, then remaining drug crushed 80
Mesh adds 75% alcohol reflux to extract 1-2 hours, and filtrate is collected in filtering, and concentration obtains concentrate, uniform with above-mentioned volatile oil
Mixing, adds auxiliary material, pill is made.
A kind of preparation method of anaesthetic that treating asthma, it is characterised in that: by the agalloch eaglewood in bulk pharmaceutical chemicals, dalbergia wood, mountain agalloch eaglewood,
Costus root, cloves are ground into coarse powder, add distilled water, impregnate 30min, are placed in volatile oil extractor, add water, past medicine
Material liquid level 3-4cm, heating water bath collect the volatile oil that above-mentioned raw materials medicine extracts, spare, then remaining drug crushed 80
Mesh filters first with being washed under the conditions of 70 DEG C of petroleum ether to it, discards filtrate, filter residue adds 75% alcohol reflux to extract
1-2 hours, filtrate was collected in filtering, and concentration obtains concentrate, uniformly mixes with above-mentioned volatile oil, add auxiliary material, pill is made.
The beneficial effects of the present invention are: providing a kind of pair of asthma with significant curative effect, and the mechanism of action is clear, effective portion
Position is clear, and taking dose is small, quickly effective, has no toxic side effect, convenient for the anaesthetic for the treatment asthma taken, and breaks traditional mongolian medicine
The preparation method that crushes of crude drug have developed a kind of environmentally protective using modern science and technology, preparation method is simple, with above-mentioned anaesthetic
The preparation method to match has played the maximum effect of above-mentioned anaesthetic.
Specific embodiment
The first embodiment:
A kind of anaesthetic for treating asthma is developed, the bulk pharmaceutical chemicals including following parts by weight: 10-15 parts of oxtongue, Banlangen
0.5-0.7 part, 0.06-0.08 part of alantolactone, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin, Kaempferol
0.05-0.07 part.It is preferred that 12.5 parts of oxtongue, 0.6 part of Banlangen, 0.07 part of alantolactone, 0.6 part of ursolic acid, hiding
1.5 parts of carthamin, 0.06 part of Kaempferol.
Preparation method: crushed 80 meshes for the bulk pharmaceutical chemicals, mixes, powder or water-bindered pill agent or tablet is made.It is preferred that water
Ball.
Instructions of taking: oral, the amount of adult 0.5-1.5g(amount containing main ingredient — that is, the drug in addition to auxiliary material)/time, it takes daily
2-3 times.
Bulk pharmaceutical chemicals brief introduction:
Oxtongue, anaesthetic name, Xi Tu is such as ancient (Four-Volume Medical Code), alias: rifle knife dish, uncommon day one be bright to account for, Cha Xiba mono- its its
Lattice, scientific name: PicrisjaponicaThunb. (composite family).Chemical component: aerial part contains flavone compound, alkaloid.Leaf,
Colored and Pi Zhonghan oleanolic acid, taraxerol (Taraxerol), ursolic acid, betulic acid, Lupeol (Lupeol), β-
Sitosterol, β-amyrin.Also contain terpene substances.Nature,taste and action: it is Chinese medicine bitter, pungent, it is cool in nature.Purging fire for removing toxin, stasis-dispelling and pain-killing, benefit
Urine.Anaesthetic bitter is cool in nature, rough.Heat-clearing is detoxified, and detumescence is killed " viscous ", is relieved pain.Chinese medicine controls ulcerative carbuncle pyogenic infections, and traumatic injury is let out
It rushes down, difficult urination.Anaesthetic controls pestilence, influenza, battle array shouting pain, " hair disease ", acute mastitis.
Banlangen is extracted from radix sophorae, Sophora alopecuroide, root of subprostrate sophora etc., and micro- smelly, taste is extremely bitter, have draw it is moist.In ethyl alcohol, chlorine
It easily dissolves in imitative, acetone, is largely dissolved in ether.Pharmacological action are as follows: increasing leukocyte number reinforces immunity of organisms, and
Play the infection such as anti-shigella dysenteriae, dermatophyte, Amoeba, trichomonad.Still there is diuresis, relieving asthma, hypnosis, the mistake of the anti-rhythm of the heart
The effects of normal.It is for oral administration to treat acute bacillary dysentery, tonsillitis, mazoitis, pelvic inflammatory disease, lymphnoditis, upper sense, bronchitis, asthma
Breath, arrhythmia cordis, leucocyte are low etc., can also be effective to psoriasis and insomnia.Kuh-seng external application can control trichomoniasis, women's vulva scabies
Itch, cervicitis, eczema etc..(the medical grade matrine that Xi'an Sen Zhuo Biotechnology Co., Ltd improves)
Alantolactone, English name: alantolactone, molecular formula: C15H20O2, plant origin: compositae plant elecampane
Dissolubility: the dry root of Inula helenium L is soluble in ethyl alcohol, chloroform, benzene, is practically insoluble in water.According to relevant information,
The anthelmintic action of alantolactone is good compared with santonin effect and toxicity is lower.Antibacterial action exists through in vitro test, alantolactone
When 0.1 μ g/ml concentration, the growth of tubercle bacillus can be inhibited.The cavy of Bacillus tuberculosis is infected, alantolactone is taken orally,
Energy delayed onset, but cannot completely inhibit.Trichophyton mentagrophytes, size can be completely inhibited when concentration is 30,40,70 and 80ug/ml
The growth of pityrosporion ovale, Paecilomycesliacinus and Rhizotonia.The spore of complete inhibition Fusar-iumsolani is sprouted
Hair can block glucose-V-14C to seep synthetic macromolecule completely in 400ug/ml.
Ursolic acid, original name Ursolic Acid, also known as malol, ursolic acid, has special smell, is to be present in natural plant
One of object pentacyclic triterpenoid.Still it is soluble in methanol, acetone, pyridine, not soluble in water and petroleum ether.Liver protection, anti-liver
Inflammation effect, ursolic acid clinical manifestation have it is significant and reduce rapidly glutamic-pyruvic transaminase, serum transaminase, recession yellow subcutaneous ulcer, improve a poor appetite,
Anti-fibrosis and the effect for restoring liver function, have the characteristics that quick, short treating period, effect stability." anti-hepatitis Chinese medicine is a kind of new
The research and development of medicine malol and its preparation " project makes substantial progress, and is put into national " 863 " plan in 2002, obtains country
1,000,000 yuan of research fund funds, become national great research topic (2002AA2Z3217).Ursolic acid also to it is a variety of it is carcinogenic,
Promoting cancer object has resistant function, and research finds that ursolic acid can obviously inhibit HL-60 cell Proliferation, and induces its apoptosis;It can make mouse
The significant raising of macrophage phagocytic function, Human tongue cancer cell line strain TSCCa cell Proliferation can be inhibited, to the half of TSCCa cell
The inhibition dosage of number growth is about 12.5 μm of olL-1, shows as a certain amount effect relationship interior for 24 hours;In situ hybridization is shown
Ursolic acid is related with the original position expression of nuclear factor is inhibited to the inhibiting effect of TSCCa cell.In vivo studies proves ursolic acid
Body's immunity can be remarkably reinforced.Illustrate that the antitumor action of ursolic acid is extensive, ursolic acid, which very likely becomes low toxicity, to be had
The new anticancer drug of effect.Ursolic acid is a stronger antioxidant.There is experiment to show that ursolic acid can inhibit arachidonic acid
5-LO, peroxidase activity in metabolic process prevent prostaglandin and leukotriene from generating, this may be ursolic acid suppression
The reason of inflammatory reaction processed, anti-lipid peroxidation object.Subbaramaiah etc. is research shows that ursolic acid can inhibit on human milk gland
Thus the transcription of Cycloxygenase in chrotoplast also inhibits prostaglandin to generate.The antioxidation of ursolic acid resists human body
Aging, skin nti-freckle, pigment of dispelling have positive effect;Antibacterial, anti-inflammatory and antiviral, it is real that Tapondjou etc. passes through acetic acid twisting
It tests with hot plate method it is experimentally confirmed that ursolic acid has similar antiinflammatory and bacteriostatic functions with hydroxyursolicacid.Ursolic acid can inhibit first respectively
The generation of the superoxides of acyl methionyl-leucyl-phenylalanine (fMLP) and arachidonic acid-induction.By ursolic acid and
FMLP is added in cell culture fluid, and ursolic acid is in the 45ku protein tyrosine phosphatase that dose-dependent inhibition is induced by fMLP.
Ursolic acid also has trypanocidal activity, and after 2 h are incubated under the concentration of 2gL, the activity of schizotrypanum cruzi flagellated body is pressed down completely
System;Reducing blood lipid, antiatherosclerosis, the effect for reducing blood glucose: ursolic acid can reduce rabbit and rat cholesterolemia
(44%) and B- lipoprotein levels (50%), there is reducing blood lipid, study of anti-atherogenic effect.Ursolic acid can improve dyslipidemia
The caused deficiency of liver-yin and kidney-yin, tinnitus, dry, few bedroom, irritable, limb fiber crops are cold, just diseases, the blood lipid curative effect total effective rate such as knot are
95% .To the inhibiting effect of AIDS virus: human immunodeficiency virus (HIV) is Immune Deficiency Syndrome
(AIDS) virulence factor.Ursolic acid has strong inhibiting effect to HIV-1 proteinase activity to field English etc. through clinical trials,
Its 50% inhibition concentration (IC50) is 8 μm of ol/L.HIV-1 protease is a homodimer enzyme, and ursolic acid may be by
The dimerization of HIV-1 protease is inhibited to be used to inhibit the activity of HIV-1 protease, so that hiv protease be inhibited to play a role.Bear
Tartaric acid Central nervous system has apparent stable and cooling effect.
Crocin (Crocin) is the ester that crocetin and two molecule gentiobioses are combined into, and contains crocetin
Dimethyl ester, Picrocrocin about 2%, volatile oil 0.4~1.3%.Pharmacological action: cholagogue.
Kaempferol, yellow fine powder.Kaempferol belongs to flavonols, yellow needles, 276 DEG C of -278 DEG C of kaempferia galangas of fusing point
Phenol is slightly soluble in water, is dissolved in hot ethanol, ether and alkali.Pharmacological action: antibacterial, to staphylococcus aureus and Pseudomonas aeruginosa, typhoid fever bar
Bacterium, shigella dysenteriae have inhibiting effect.Bronchitis is treated in cough-relieving.Press down enzyme, inhibits eye aldose reductase, be conducive to diabetes
The treatment of cataract.It can inhibit lymphopoiesis when concentration is 1 × 10-4mol/L with mutagens activity.It is main to use
In anticancer, inhibit fertility, anti-epileptic, anti-inflammatory, antioxidant, spasmolysis, antiulcer, cholagogue diuretics, cough-relieving.Kaempferol has anti-
Cancer inhibits fertility, anti-epileptic, anti-inflammatory, antioxidant, spasmolysis, antiulcer, cholagogue diuretics, cough-relieving and other effects.
Prescription analysis: in above-mentioned prescription, oxtongue, flavour of a drug are bitter, cool in nature, rough, heat-clearing, detoxify, and detumescence is killed " viscous ", relieve pain,
With antibacterial, there is the Kaempferol of inhibiting effect to control for we staphylococcus aureus and Pseudomonas aeruginosa, typhoid bacillus, shigella dysenteriae
The main ingredient for treating asthma is aided with Banlangen increasing leukocyte number, reinforces immunity of organisms, the further antibacterial of alantolactone, bear
Tartaric acid Central nervous system has the ursolic acid of apparent stable effect to alleviate the complication such as asthma bring palpitaition, crocin
Cholagogue is used to alleviate asthma bring complication.Said medicine complements each other, co-therapies asthma.
Experimental example brief introduction:
Since 2010, on the basis of not finding toxic side effect by toxicological experiment, a large amount of clinic trial is carried out, has been taken
Obtained satisfied curative effect.Experimental conditions are as follows:
Diagnostic criteria: " diagnostic criteria of bronchial asthma " (the China's knot formulated referring to Chinese Medical Association's respirology meeting branch
Core and breathing magazine, 2003,26(3): 132) and " Mongolian medicine's Illnesses Diagnoses criterion of therapeutical effect " (Beijing: Nationalities Press, 2007:
420-421).
Criterion of therapeutical effect: referring to the curative effect mark for the bronchial asthma that Chinese Medical Association's respirology meeting branch's asthma group is formulated
Standard is drafted.Clinic control: patient's asthma symptoms complete incidence graph, and 80% or more of the reachable predicted value of FEVI (respiratory capacity), or exhale
15% or less gas peak flow velocity diurnal fluctuation;It is effective: patient's asthma attack with it is substantially reduced before treatment, and FEVI is in predicted value
Between 60% -79% or End--tidal PCO_2 diurnal fluctuation is between 15% -20%;Improve: patient's asthma symptoms mitigate, but FEVI
Predicted value 60% hereinafter, or End--tidal PCO_2 diurnal fluctuation 20% or more;It is invalid: the clinical symptoms and FEVI of patient, or
The equal no significant improvement or aggravation of climacteric flow velocity.
Since 2010, clinic aspiration asthmatic patient 40, male 20, women 20, the age at 26-70 years old, the course of disease
1-10 years, take drug of the present invention, 0.5-1.5g(amount containing main ingredient)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of 15 days,
The good medicine of disease stops.Experimental result is shown in the following table 1:
Clinic control rate=[clinic control (example)/sum (example)] * 100%
Obvious effective rate=[effective (example)/total (example)] * 100%
Improvement rate=[improve (example)/total (example)] * 100%
Total effective rate=[total (example)-is invalid (example)] * 100%
By table as it can be seen that there is good curative effect with drug therapy asthma of the present invention.
The above-mentioned patient of follow-up 1 year, without any toxicity, more after recidivist 2 people, led by enviromental allergen stimulation
It causes.
Second of embodiment:
On the basis of the first embodiment, the raw material medicaments in part by weight is added: 5-7 parts of fructus choerospondiatis, 5-7 parts of falsespiraea tree bark,
9-11 parts of Inula britannica chinensis, 5-7 parts of myrobalan.That is 10-15 parts of oxtongue, 0.5-0.7 part of Banlangen, alantolactone 0.06-
0.08 part, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin, 0.05-0.07 part of Kaempferol, 5-7 parts of fructus choerospondiatis, falsespiraea tree bark
5-7 parts, 9-11 parts of Inula britannica chinensis, 5-7 parts of myrobalan.It is preferred that 12.5 parts of oxtongue, 0.6 part of Banlangen, alantolactone
It 0.07 part, 0.6 part of ursolic acid, 1.5 parts of crocin, 0.06 part of Kaempferol, 6 parts of fructus choerospondiatis, 6 parts of falsespiraea tree bark, 10 parts of Inula britannica chinensis, scolds
6 parts of son.
Preparation method: crushed 80 meshes for the bulk pharmaceutical chemicals, mixes, powder or water-bindered pill agent or tablet is made.It is preferred that water
Ball.
Instructions of taking: oral, the amount of adult 1-2g(amount containing main ingredient — that is, the drug in addition to auxiliary material)/time, take daily 2-3
It is secondary.
Bulk pharmaceutical chemicals brief introduction:
Fructus choerospondiatis, such as very-Chinese herbaceous peony is husky, peaceful Chinese herbaceous peony is husky, pearl as looked into a bar loud, high-pitched sound very much for Mongolian name pearl.For Anacardiaceae plant Spondias axillaris
The drying fruit stone of (Choerospondias axillaris<Roxb.>Burtt et Hill).Sample it is sour, sweet, mild-natured, greasy,
It is heavy, soft.The effect of having clearing away the heart-fire, improving heart function.For heart shouting pain, angina pectoris, heart failure disease etc..
Pearl does also known as falsespiraea tree bark, and Mongolian name Bo Rele gigue is slow, and different name, which is done, reaches loud, high-pitched sound day, cold-black day Gus of A Ersi,
For the stem of rosaceous plant library leaf raspberry.Sweet in flavor, micro-pungent, it is mild-natured, it imitates soft.Major function: refining epidemic disease heat, cough-relieving, conditioning engine body.
Cure mainly warm disease initial stage heat, intermal comflict heat, flu, oldness lung heat, coughing with a lot of sputum, asthma etc..
Inula britannica chinensis, from the drying of compositae plant Inula britannica chinensis Thunb. or Inula britannica Inula bntannica L.
Capitulum.Chemical component: 1. flavonoids: Quercetin, quercimeritrin, Isoquercitrin, quercetagitrin, luteolin, Mongolian oak
Pi Su-7-glucuronic acid glycoside etc..2. organic acid: P-hydroxybenzoic acid, protocatechuic acid, the blue acid of fragrant first, syringic acid,
P-hydroxyphenylaceticacid, p-coumaric acid, caffeic acid, ferulic acid, salicylic acid.3. esters: 3/3,16/3-dihydroxy lupeol-3
The neat pier -13 (18) of palmitate-alkene -3- acetic acid esters, Sesquiterpene etc..4. other: table is without bridle alcohol armomadendrin, paddy steroid
Base -3- glycoside etc..
Myrobalan, Mongolian name arrara, must circle it is refined, A Malida, volume wood mattress is cried out, Da Lalaha, it is old it is emerging not.For combretaceae
Plant myrobalan (Terminalia chebula Retz), villus myrobalan (Terminalia chebula
Retz.Var.tomentella Kurt), Henghe myrobalan (Terminalia chebula Retz.Var.gengetica
Roxb dry mature fruit).(up to 20% -40%) containing a large amount of tannins, myrobalan mainly contains triterpene acids, nutgall acyl grape
The substances such as sugar, the simple ester type compound of nutgall acyl and Anthraquinones have the pharmacology such as antibacterial, heart tonifying, anti-oxidant and anticancer living
Property.Its main component is chebulinic acid, terchebin etc..This product puckery, it is mild-natured.There are all diseases caused by three numbness, improves voxel
I.e. three, the effect of removing toxic substances, it is suitable for conspicuous according to, Xi La, Ba Dagan complication and all diseases of polymerism.
Prescription analysis: it in above-mentioned prescription, joined on the basis of the first embodiment: falsespiraea tree bark, Inula britannica chinensis, fructus choerospondiatis,
Myrobalan, wherein falsespiraea tree bark, Inula britannica chinensis, further enhance the cough-relieving of prescription, the function of sending down abnormally ascending, further treat asthma, are added
Fructus choerospondiatis auxiliary ursolic acid further alleviate the complication such as asthma bring palpitaition, myrobalan is used to coordinating the drug actions of a prescription.Said medicine phase
It is auxiliary to coordinate, co-therapies asthma.
Experimental example brief introduction:
Since 2010, on the basis of not finding toxic side effect by toxicological experiment, a large amount of clinic trial is carried out, has been taken
Obtained satisfied curative effect.Experimental conditions are as follows:
Diagnostic criteria: " diagnostic criteria of bronchial asthma " (the China's knot formulated referring to Chinese Medical Association's respirology meeting branch
Core and breathing magazine, 2003,26(3): 132) and " Mongolian medicine's Illnesses Diagnoses criterion of therapeutical effect " (Beijing: Nationalities Press, 2007:
420-421).
Criterion of therapeutical effect: referring to the curative effect mark for the bronchial asthma that Chinese Medical Association's respirology meeting branch's asthma group is formulated
Standard is drafted.Clinic control: patient's asthma symptoms complete incidence graph, and 80% or more of the reachable predicted value of FEVI (respiratory capacity), or exhale
15% or less gas peak flow velocity diurnal fluctuation;It is effective: patient's asthma attack with it is substantially reduced before treatment, and FEVI is in predicted value
Between 60% -79% or End--tidal PCO_2 diurnal fluctuation is between 15% -20%;Improve: patient's asthma symptoms mitigate, but FEVI
Predicted value 60% hereinafter, or End--tidal PCO_2 diurnal fluctuation 20% or more;It is invalid: the clinical symptoms and FEVI of patient, or
The equal no significant improvement or aggravation of climacteric flow velocity.
Since 2010, clinic aspiration asthmatic patient 39, male 19, women 20, the age at 26-70 years old, the course of disease
1-10 years, take drug of the present invention, 1-2g(amount containing main ingredient)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of 15 days, disease is good
Medicine stops.Experimental result is shown in the following table 2:
Clinic control rate=[clinic control (example)/sum (example)] * 100%
Obvious effective rate=[effective (example)/total (example)] * 100%
Improvement rate=[improve (example)/total (example)] * 100%
Total effective rate=[total (example)-is invalid (example)] * 100%
By table as it can be seen that there is good curative effect with drug therapy asthma of the present invention.Clinic control rate, total effective rate are above first
Kind of embodiment, it is seen that added fructus choerospondiatis, falsespiraea tree bark, Inula britannica chinensis, myrobalan enhance the effect of prescribed treatment asthma.
The above-mentioned patient of follow-up 1 year, without any toxicity, more after recidivist 2 people, led by enviromental allergen stimulation
It causes.
The third embodiment:
On the basis of second of embodiment, the raw material medicaments in part by weight is added: 5-7 parts of Radix picrorrhizae, common bombax flower 5-7
Part, 9-11 parts of nutmeg, 9-11 parts, 6-8 parts of Fructus meliae toosendan of vomiting nut (system).That is: 10-15 parts of oxtongue, Banlangen
0.5-0.7 part, 0.06-0.08 part of alantolactone, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin, Kaempferol
0.05-0.07 part, 5-7 parts of fructus choerospondiatis, 5-7 parts of falsespiraea tree bark, 9-11 parts of Inula britannica chinensis, 5-7 parts of myrobalan, 5-7 parts of Radix picrorrhizae, wood
5-7 parts of cotton, 9-11 parts of nutmeg, 9-11 parts, 6-8 parts of Fructus meliae toosendan of vomiting nut (system).It is preferred that 12.5 parts of oxtongue, it is bitter
0.6 part of total alkali of ginseng, 0.07 part of alantolactone, 0.6 part of ursolic acid, 1.5 parts of crocin, 0.06 part of Kaempferol, 6 parts of fructus choerospondiatis,
6 parts of falsespiraea tree bark, 10 parts of Inula britannica chinensis, 6 parts of myrobalan, 6 parts of Radix picrorrhizae, 6 parts of common bombax flower, 10 parts of nutmeg, 10 parts of vomiting nut (system), river
7 parts of chinaberry.
Preparation method: crushed 80 meshes for the bulk pharmaceutical chemicals, mixes, powder or water-bindered pill agent or tablet is made.It is preferred that water
Ball.
Instructions of taking: oral, adult 1.5-2.0g(amounts containing main ingredient)/time, it takes daily 2-3 times.
Bulk pharmaceutical chemicals brief introduction:
Alias: Radix picrorrhizae cuts lonely dew pool, Hu Lian, Tibet picrorhiza rhizome, is the root of scrophulariaceae Tibet picrorhiza rhizome and Radix picrorrhizae
Stem.Latin name PicrorhizascrophulariifloraPennell.Main component: root contains kutkin (Kutkin), D-
Mannitol (D-Mannitol), vanillic acid (Vanillic acid), kutkinol (Kutkiol), kutkisterol
(Kutkisterol) and acetovanilone (Apocynin), still isolate bitter principle kutkin I (Picroside I),
Piperonyl methyl acetone, III, of kutkin still analyse to obtain cinnamoyl-α-D- glucopyranose (Cinnamoyl- α-D-
) and 6- cinnamoyl-β-D- glucopyranose (6-Cinnamoyl- β-D-gluco- pyranose) glucopyranose.It is recklessly yellow
Acetovanillone (Apocynine) is analysed to obtain in extract even.Radix picrorrhizae has reducing the asthenic fever, the infantile malnutrition with fever that disappears, cool blood eliminating dampness, purging fire for removing toxin
Effect, the major functions: deficiency of Yin hectic fever due to yin;Hectic fever night sweat;Infant malnutrition;Damp-heat dysentery;Jaundice;It spits blood;Bleeding from five sense organs or subcutaneous tissue;Red eye, swell pain;Carbuncle swells sore
Ulcer;Hemorrhoid pyogenic infections.
Common bombax flower, i.e. kapok petal, Mongolian name Mao Dun-haler it is special this, Ahmedabad Ma-Gus you, Lu Xingmaodun be-its
Its lattice.For the drying petal of Bombacaceae plant kapok.This product is sweet in flavor, cool in nature, puckery, blunt.There is the effect of clearing away heart-fire, lung, hot liver.For
Heart shouting pain, the cardiopyretic syndromes such as asthma.
Nutmeg, Mongolian name circle enlightening, that Ma of different name derive from the myristic seed of myristicaceae plant.Pharmacological property: acrid flavour,
It is warm-natured.Imitate it is greasy, again, it is soft.Major function: suppression is conspicuous according to tune stomach fire helps digestion, whets the appetite.Heart He Yi is cured mainly, heart shouting pain faints, is nervous,
Department's life is conspicuous according to disease, the diseases such as indigestion.
Vomiting nut (system), Mongolian name public affairs Ziller, Gao Jila, all wood up to gram, letter Pu Lebu.For before horse previous conviction plant horse or
Dry mature seed before long seed horse.It burns and makes: taking net sand to set in pot, after generally making popular with high heat, net vomiting nut is added, constantly
It stirs, scalds to taking-up when heaving and show sepia or dark-brown, weed out sand, cool, it is spare to scrape unhairing.This product bitter, cool in nature,
Gently, blunt, have and relieving asthma, heat-clearing, removing toxic substances, the effect of analgesic.For thoracic dorsal shouting pain, asthma uncomfortable in chest.
Fructus meliae toosendan, Mongolian name Ba Rula, different name cloth and-Cha Gan-Mao Dunnai-crow heat.Pharmacological property: puckery, hardship, cool in nature.Effect
Gently, light, dry, blunt.Major function: clear bar is assisted day up to dry, and scorching property Xieri Wusu Symptom, desinsection, analgesic, improving eyesight.Cure mainly hot association's day
Black element disease, Ba Dagan assist day complication, turbid heat, new heat, old heat etc..
Prescription analysis: this prescription joined nutmeg, common bombax flower enhancing treatment asthma on the basis of second of embodiment
Caused heart shouting pain, the cardiopyretic syndromes such as asthma, vomiting nut (system) are used to treat the complication thoracic dorsal shouting pain of asthma, asthma uncomfortable in chest, Hu
Coptis reducing the asthenic fever, for assisting in the treatment of complication caused by the longer patient of asthma medical history-abnormal heat disease, clear bar of Fructus meliae toosendan is assisted up to dry
Day, scorching property Xieri Wusu Symptom assists heat-clearing, and above-mentioned all medicines are combined with the medicine of second of embodiment, complemented each other, and co-therapies are roared
Asthma.
Experimental example brief introduction:
Since 2010, on the basis of not finding toxic side effect by toxicological experiment, a large amount of clinic trial is carried out, has been taken
Obtained satisfied curative effect.Experimental conditions are as follows:
Diagnostic criteria: " diagnostic criteria of bronchial asthma " (the China's knot formulated referring to Chinese Medical Association's respirology meeting branch
Core and breathing magazine, 2003,26(3): 132) and " Mongolian medicine's Illnesses Diagnoses criterion of therapeutical effect " (Beijing: Nationalities Press, 2007:
420-421).
Criterion of therapeutical effect: referring to the curative effect mark for the bronchial asthma that Chinese Medical Association's respirology meeting branch's asthma group is formulated
Standard is drafted.Clinic control: patient's asthma symptoms complete incidence graph, and 80% or more of the reachable predicted value of FEVI (respiratory capacity), or exhale
15% or less gas peak flow velocity diurnal fluctuation;It is effective: patient's asthma attack with it is substantially reduced before treatment, and FEVI is in predicted value
Between 60% -79% or End--tidal PCO_2 diurnal fluctuation is between 15% -20%;Improve: patient's asthma symptoms mitigate, but FEVI
Predicted value 60% hereinafter, or End--tidal PCO_2 diurnal fluctuation 20% or more;It is invalid: the clinical symptoms and FEVI of patient, or
The equal no significant improvement or aggravation of climacteric flow velocity.
Since 2010, clinic aspiration asthmatic patient 40, male 20, women 20, the age at 26-70 years old, the course of disease
1-10 years, take drug of the present invention, 1.5-2.0g(amounts containing main ingredient)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of 15 days,
The good medicine of disease stops.Experimental result is shown in the following table 3:
Clinic control rate=[clinic control (example)/sum (example)] * 100%
Obvious effective rate=[effective (example)/total (example)] * 100%
Improvement rate=[improve (example)/total (example)] * 100%
Total effective rate=[total (example)-is invalid (example)] * 100%
By table as it can be seen that there is good curative effect with drug therapy asthma of the present invention.Clinic control rate, obvious effective rate, total effective rate are equal
Higher than second embodiment, it is seen that Radix picrorrhizae, common bombax flower, nutmeg, vomiting nut (system), the Fructus meliae toosendan of addition can be further
Enhance the effect of prescribed treatment asthma.
The above-mentioned patient of follow-up 1 year, without any toxicity, more after recidivist 1 people, caused by enviromental allergen stimulation.
4th kind of embodiment: on the basis of the third embodiment, the raw material medicaments in part by weight is added: agalloch eaglewood 5-7
Part, 12-13 parts of dalbergia wood, 12-13 parts of mountain agalloch eaglewood, 9-11 parts of costus root, 9-11 parts of cloves.That is: 10-15 parts of oxtongue, it is bitter
0.5-0.7 part of total alkali of ginseng, 0.06-0.08 part of alantolactone, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin, kaempferia galamga
0.05-0.07 part of phenol, 5-7 parts of fructus choerospondiatis, 5-7 parts of falsespiraea tree bark, 9-11 parts of Inula britannica chinensis, 5-7 parts of myrobalan, 5-7 parts of Radix picrorrhizae,
5-7 parts of common bombax flower, 9-11 parts of nutmeg, 9-11 parts of vomiting nut (system), 6-8 parts of Fructus meliae toosendan, 5-7 parts of agalloch eaglewood, dalbergia wood 12-
13 parts, 12-13 parts of mountain agalloch eaglewood, 9-11 parts of costus root, 9-11 parts of cloves.It is preferred that 12.5 parts of oxtongue, Banlangen 0.6
Part, 0.07 part of alantolactone, 0.6 part of ursolic acid, 1.5 parts of crocin, 0.06 part of Kaempferol, 6 parts of fructus choerospondiatis, 6 parts of falsespiraea tree bark,
10 parts of Inula britannica chinensis, 6 parts of myrobalan, 6 parts of Radix picrorrhizae, 6 parts of common bombax flower, 10 parts of nutmeg, 10 parts of vomiting nut (system), sinks by 7 parts of Fructus meliae toosendan
It is 6 parts, 12.5 parts of dalbergia wood, 12.5 parts of mountain agalloch eaglewood, 10 parts of costus root, 10 parts of cloves fragrant.
Preparation method one: crushed 80 meshes for the bulk pharmaceutical chemicals, mixes, powder or water-bindered pill agent or tablet is made.It is preferred that
The water-bindered pill.
Instructions of taking: oral, the amount of adult 1.5-2.5g(amounts containing main ingredient — that is, the drug in addition to auxiliary material)/time, it takes daily
2-3 times.
Preparation method two: by the agalloch eaglewood in bulk pharmaceutical chemicals, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds steaming
Distilled water impregnates 30min, is placed in volatile oil extractor, adds water, past medicinal material liquid level 3-4cm, heating water bath, in collection
The volatile oil that bulk pharmaceutical chemicals extract is stated, it is spare, then remaining drug be crushed into 80 meshes, add 75% alcohol reflux to extract 1-
2 hours, filtrate was collected in filtering, and concentration obtains concentrate, uniformly mixes with above-mentioned volatile oil, add auxiliary material, pill is made.
Instructions of taking: oral, the amount of adult 0.5-1.5g(amount containing main ingredient — that is, the drug in addition to auxiliary material)/time, it takes daily
2-3 times.
Preparation method three: by the agalloch eaglewood in bulk pharmaceutical chemicals, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds distillation
Water impregnates 30min, is placed in volatile oil extractor, adds water, and past medicinal material liquid level 3-4cm, heating water bath is collected above-mentioned
The volatile oil that bulk pharmaceutical chemicals extract, it is spare, then remaining drug be crushed into 80 meshes, to it under the conditions of first using 70 DEG C of petroleum ether
It is washed, is filtered, discard filtrate, filter residue adds 75% alcohol reflux to extract 1-2 hours, and filtrate is collected in filtering, and concentration obtains
Concentrate uniformly mixes with above-mentioned volatile oil, adds auxiliary material, pill is made.
Instructions of taking: oral, the amount of adult 0.5-1.5g(amount containing main ingredient — that is, the drug in addition to auxiliary material)/time, it takes daily
2-3 times.
Bulk pharmaceutical chemicals brief introduction:
Agalloch eaglewood, Mongolian name Ah loud, high-pitched sound are the timber containing resin of Isolated From Thymelaeaceae Species agalloch eaglewood or suspension culture of Aquilaria sinensis such as.Acrid flavour, hardship, it is cool in nature.
It imitates heavy, soft, greasy, dry, blunt, soft.Major function: suppression is conspicuous according to, heat-clearing, only shouting pain, benefit breathing.It is hot to cure mainly the heart, heart shouting pain, palpitaition,
Asthma, master pulse it is conspicuous according to.
Mountain agalloch eaglewood, Mongolian name Alxa Ah loud, high-pitched sound such as, Ao youth Ah loud, high-pitched sound is such as.For the dry duramen of Oleaceae plants Helan Mountain cloves
Or root, the same agalloch eaglewood of this product nature and flavor, effect.
Dalbergia wood, such as, different name A Maer, Ah loud, high-pitched sound are pulse family such as-Gao Wude " errorless anaesthetic mirror " to Mongolian name Ulan-Ah loud, high-pitched sound
The root heartwood of plant dalbergia wood wingceltis.Pharmacological property: acrid flavour, it is cool in nature.It imitates greasy.Major function: suppression is conspicuous according to heat-clearing relieves pain.It is conspicuous to cure mainly the heart
According to, lifeblood is conspicuous to tremble according to disease, and dizzy, insomnia is ill at ease and full of dread, and it is conspicuous mutually to be won according to blood, it is hot between mountains and rivers.
Radix aucklandiae is the common name of compositae plant Aplotaxis auriculata and radix jurineae.Aplotaxis auriculata (scientific name: auureacotu) also known as costus root
Or dutchmanspipe root, belong to composite family Genus Saussurea.Radix aucklandiae Aucklandia lappa Decne, Mongolian name such as reach, sand bubble such as reach, Ma slave
Such as reach.For the dry root of compositae plant radix aucklandiae (Aucklandia lappa Decen.).This product acrid flavour, hardship, warm-natured, greasy, puckery,
Gently;Dispel Ba Dagan, broken ruffian, adjusts voxel, restrains purulence, phlegm, anti-erosion, flat qi and blood is mutually won, analgesic and other effects.Radix aucklandiae containing dehydrogenation
Lactone (dehydrocostuslactone), the volatile oil such as costunolide (costunolide) and a variety of amino acid.
Cloves, Mongolian name Gao Ledou-Bao Ru, different name Li Xi, Li Xisangsi " errorless anaesthetic mirror ", volume day-Gao Ledou-
Treasured is eaten.From hill gooseberry can plant of clove bud.Acrid flavour, slight bitter, it is warm-natured.It imitates heavy, greasy, solid, soft, dry.Major function: dispelling
It is cold, it dispels conspicuous according to fire tuning helps digestion, appetizing, removing toxic substances, table rash, throat.It is conspicuous according to, heart He Yi to cure mainly master pulse, demented, acne rash is silent.
Prescription analysis: this prescription is the addition agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, fourth on the basis of the third embodiment
Perfume (or spice), this five kinds of Chinese medicine all have pungent scattered gas, and wherein agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, cloves can press down conspicuous according to heat-clearing, only shouting pain is assisted
Help fructus choerospondiatis, ursolic acid further to alleviate the complication such as asthma bring palpitaition, costus root dispel Ba Dagan, adjust voxel, flat qi and blood
Asthma bring pectoralgia is further alleviated in Xiang Bo, analgesic, and said medicine complements each other co-therapies asthma.
Preparation method analysis: first is that traditional anaesthetic preparation method the water-bindered pill is made in said medicine crushing by preparation method;System
Preparation Method two improves preparation method, by due to the dissolubility for the effective component that effect is played in prescription it is different, according to
Characteristic is first extracted the effective component of performance curative effect of agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves this five kinds of Chinese medicine,
There is the ingredient by the performance curative effect of remaining drug to be extracted, then again mix the two, suitable dosage form-ball is made
Agent.By this preparation method, the submember for not playing main function in prescription is eliminated, the performance in prescription has been refined
The ingredient of main function, specifies active component, reduces taking dose, facilitates patients, thus from another point of view indirectly
Enhance the therapeutic effect of drug, expand therapeutic domain, because of anaesthetic flavour of a drug, medication dose is big, cannot adhere to taking and
It refuses to take medicine, therapeutic effect reduction, therapeutic domain is caused to be substantially reduced;Preparation method three is on the basis of preparation method two to medicine
The active component of object has carried out further refining, and agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves five kinds of Chinese medicine are dissolved in petroleum ether
Invalid components reject, keep effective component more accurate, medication dose can further decrease, and also eliminate invalid components to trouble
Other ill-effects of person.
Experimental example brief introduction:
Since 2010, on the basis of not finding toxic side effect by toxicological experiment, a large amount of clinic trial is carried out, has been taken
Obtained satisfied curative effect.Experimental conditions are as follows:
Diagnostic criteria: " diagnostic criteria of bronchial asthma " (the China's knot formulated referring to Chinese Medical Association's respirology meeting branch
Core and breathing magazine, 2003,26(3): 132) and " Mongolian medicine's Illnesses Diagnoses criterion of therapeutical effect " (Beijing: Nationalities Press, 2007:
420-421).
Criterion of therapeutical effect: referring to the curative effect mark for the bronchial asthma that Chinese Medical Association's respirology meeting branch's asthma group is formulated
Standard is drafted.Clinic control: patient's asthma symptoms complete incidence graph, and 80% or more of the reachable predicted value of FEVI (respiratory capacity), or exhale
15% or less gas peak flow velocity diurnal fluctuation;It is effective: patient's asthma attack with it is substantially reduced before treatment, and FEVI is in predicted value
Between 60% -79% or End--tidal PCO_2 diurnal fluctuation is between 15% -20%;Improve: patient's asthma symptoms mitigate, but FEVI
Predicted value 60% hereinafter, or End--tidal PCO_2 diurnal fluctuation 20% or more;It is invalid: the clinical symptoms and FEVI of patient, or
The equal no significant improvement or aggravation of climacteric flow velocity.
Since 2010, clinic aspiration asthmatic patient 119, male 60, women 59, the age is sick at 26-70 years old
Journey 1-10 years, three groups, under the same terms are randomly divided into, drug made from three kinds of preparation methods of this prescription is taken respectively, takes preparation
The instructions of taking of drug made from method one: 1.5-2.5g(amounts containing main ingredient)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of
15 days, the good medicine of disease stopped;Take the instructions of taking of drug made from preparation method two: 0.5-1.5g(amount containing main ingredient)/time, one day 3
It is secondary, it takes 3 course for the treatment of, a course for the treatment of 15 days, the good medicine of disease stops;Take the instructions of taking of drug made from preparation method two: 0.5-
1.5g(amount containing main ingredient)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of 15 days, the good medicine of disease stops;Experimental result is shown in the following table 4:
Clinic control rate=[clinic control (example)/sum (example)] * 100%
Obvious effective rate=[effective (example)/total (example)] * 100%
Improvement rate=[improve (example)/total (example)] * 100%
Total effective rate=[total (example)-is invalid (example)] * 100%
By table as it can be seen that there is good curative effect with drug therapy asthma of the present invention.By above-mentioned three kinds of preparation methods to having a competition
Test as it can be seen that preparation method also have a large impact on the drug effect of prescription, and preparation method three better than preparation method two due to
Preparation method one, and each dose of preparation method two, three is greatly lowered compared with preparation method one, facilitates patients.
The above-mentioned patient of follow-up 1 year, without any toxicity, more after recidivist 1 people, caused by enviromental allergen stimulation.
5th kind of embodiment:
On the basis of previous embodiment, described 0.5-0.7 part of Banlangen is substituted by 5-7 parts of kuh-seng, in elecampane
0.06-0.08 part of ester is substituted by 5-6 parts of elecampane, and 0.5-0.7 part of ursolic acid, 1-2 parts of crocin by 38-42 parts of Cape jasmines
Son substitution, 0.05-0.07 part of Kaempferol is substituted by 5-7 parts of kaempferia galamgas.It is preferred that on the basis of the 4th kind of embodiment, it is described
0.5-0.7 part of Banlangen is substituted by 5-7 parts of kuh-seng, and 0.06-0.08 part of alantolactone is substituted by 5-6 parts of elecampane,
0.5-0.7 part of ursolic acid, 1-2 parts of crocin are substituted by 38-42 parts of cape jasmines, and 0.05-0.07 part of Kaempferol by 5-7 parts
Kaempferia galamga substitution, that is, form prescription: 10-15 parts of oxtongue, 5-7 parts of kuh-seng, and 5-6 parts of elecampane, 38-42 parts of cape jasmine, kaempferia galamga
5-7 parts, 5-7 parts of fructus choerospondiatis, 5-7 parts of falsespiraea tree bark, 9-11 parts of Inula britannica chinensis, 5-7 parts of myrobalan, 5-7 parts of Radix picrorrhizae, common bombax flower
5-7 parts, 9-11 parts of nutmeg, 9-11 parts of vomiting nut (system), 6-8 parts of Fructus meliae toosendan, 5-7 parts of agalloch eaglewood, 12-13 parts of dalbergia wood,
12-13 parts of mountain agalloch eaglewood, 9-11 parts of costus root, 9-11 parts of cloves.
Preparation method one: crushed 80 meshes for the bulk pharmaceutical chemicals, mixes, powder or water-bindered pill agent or tablet is made.It is preferred that
The water-bindered pill.
Instructions of taking: oral, the amount of adult 2-3g(amounts containing main ingredient — that is, the drug in addition to auxiliary material)/time, take daily 2-3
It is secondary.
Preparation method two: by the agalloch eaglewood in bulk pharmaceutical chemicals, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds steaming
Distilled water impregnates 30min, is placed in volatile oil extractor, adds water, past medicinal material liquid level 3-4cm, heating water bath, in collection
The volatile oil that bulk pharmaceutical chemicals extract is stated, it is spare, then remaining drug be crushed into 80 meshes, add 75% alcohol reflux to extract 1-
2 hours, filtrate was collected in filtering, and concentration obtains concentrate, uniformly mixes with above-mentioned volatile oil, add auxiliary material, pill is made.
Instructions of taking: oral, adult 1.0-1.5g(amounts containing main ingredient)/time, it takes daily 2-3 times.
Preparation method three: by the agalloch eaglewood in bulk pharmaceutical chemicals, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds distillation
Water impregnates 30min, is placed in volatile oil extractor, adds water, and past medicinal material liquid level 3-4cm, heating water bath is collected above-mentioned
The volatile oil that bulk pharmaceutical chemicals extract, it is spare, then remaining drug be crushed into 80 meshes, to it under the conditions of first using 70 DEG C of petroleum ether
It is washed, is filtered, discard filtrate, filter residue adds 75% alcohol reflux to extract 1-2 hours, and filtrate is collected in filtering, and concentration obtains
Concentrate uniformly mixes with above-mentioned volatile oil, adds auxiliary material, pill is made.
Instructions of taking: oral, adult 1.0-1.5g(amounts containing main ingredient)/time, it takes daily 2-3 times.
Bulk pharmaceutical chemicals brief introduction:
Kuh-seng, Mongolian name road bone Le-Wu Busi, Li Derui.For leguminous plant kuh-seng (Sophora flavescens Ait.)
Dry root.Containing alkaloid: matrine (matrine), oxymatrine, the alkaloid compounds such as Iosmatrine.Bitter, property
It is flat, greasy, soft.Have and promote hot maturation, sweating, dry yellow water, reconcile three the effect of.It is such as hit by stick for overall pain, dry cough is breathed out
It owes more, often stretches oneself, bitter taste, headache, the unformed heat symptom-complex such as palpitaition, epidemic disease: flu does, dutchmanspipe root, kaempferia galamga etc. are matched with pearl
With.
Elecampane: its its lattice of anaesthetic name Ma Nu, different name Ma Nubadala, Gao You-haler De Situ-.From composite family
The root of plant elecampane.Pharmacological property: it is sweet in flavor, bitter, pungent, it is mild-natured.It imitates greasy, sharp, dry, again.Major function: clear bar reaches xeothermic, Xie Heyi
Blood phase intermal comflict, middle benefit gas help digestion, appetizing, only shouting pain.Cold headache is cured mainly, pernicious shiver with cold is conspicuous to cause asthma uncomfortable in chest according to blood phase intermal comflict, vomiting
Sour regurgitation, He Yixi headache and blood-head headache.Chemical component: contain synanthrin, volatile oil, oil in main component be in elecampane
Ester, isoalantolactone, alantol etc..
Cape jasmine, Mongolian name pearl such as drawing, Gao Mosile.For the dry fruit of madder wort cape jasmine.Pharmacological property: bitter, cool in nature,
It is blunt, puckery.There is the effect of removing heat from blood, improving eyesight, the Ba Dagan that dispels is uncommon to be drawn, and nourishing is strong and adjusts voxel.For liver heat, appearance jaundice blood
Heat, bladder heat etc..It is downloaded from " Chinese pharmacy encyclopedia ".Alias: Yellow Fructus Gardeniae, mountain Cape jasmine, white toad are the fruits of madder wort cape jasmine
It is real.Constituents containing iridoid: gardenoside (gardenoside), all square rafter glucoside (geniposide), all square rafter element gentiobiose
Glucoside (genipin-1-gentiobioside), shanzhiside (shanzhiside), cape jasmine ketone glucoside (gardo-side), Paederia scandens
Glucoside methyl esters (scandoside methyl ester), all square rafter glucoside (geniposidic acid), deacetylate asperuloside
Sour (deacetyl asperulosidic acid), deacetylasperulosidic acid methyl esters (methyl deacetyl
Asperulosidate), 6 〃 of 10- acetyl group all square rafter glucoside (10-acetylgeniposide)-is to coumaric acyl square rafter elements
Gentiobiose glucoside (6 〃-p-coumaroyl genipin gentiobio-side).Contain acrylic component: chlorogenic acid again
(chlorogenic acid), its quininic acid (3, -4-di-O-caffeoyl quinic acid) of 3,4- bis--O- caffeoyls, 3-
O- coffee acyl -4-O- mustard acyl quininic acid (3-O-caffeoyl-4-O-sinapoyl quinic acid), 3,5- bis- -
O- coffee acyl -4-O- (- 3 methyl of 3- hydroxyl) glutaryl quininic acid [3,5-di-O-caffeoyl-4-O- (3-hydroxy-
3-methyl) glutaroyl quinic acid], 3,4- bis- coffee acyl -5- (3- hydroxy-3-methyl glutaryl base) quinine
Sour [3,4-dicaffeovl-5- (3-hydroxy-3-methyl glutaroyl) quinic acid], crocetin (cro-
Cetin), crocin (crocin), ursolic acid (ursolic acid), crocin glycoside (crocin
Glucoside) etc..Also contain flavones ingredient: rutin (rutin) and PEARLITOL 25C (D-mannitol), cupreol (β-
Sitosterol), choline (choline), nonacosane (nonacosane), lutein (xanthophyll) etc..Pericarp and kind
Also contain gardenoside, all square rafter glucoside, all square rafter glucoside, all square rafter in son.Flower contains Triterpenoid: gardenia acid
(gradenlic acid) A, B and gardenia acid (gardenic acid) leaf contain gardenoside, all square rafter glucoside, cape jasmine aldehyde
(cerbinal), dihydrojasmonate (methyl dihydrojasmonate), acetic acid benzyl lemon imonene (limonene), fragrant camphor tree
Alcohol (linalool) etc..Rhizome contains PEARLITOL 25C, oleanolic acid (oleanolic acid), stigmasterol (sing-masterol).
It is bitter in taste, cold, nontoxic.With purging intense heat relieving restlessness, reducing fever and causing diuresis, swelling and pain relieving, cooling blood and hemostasis, protect liver, cholagogue, decompression, calmness, only
The effects of blood, detumescence.It is usually used in treating icteric hepatitis, headache in tcm clinical practice;Jaundice with damp-heat pathogen;Stranguria;Bloody flux hematuria;Dispute
Raw sore;Sore swollen toxin;The diseases such as bruise, hypertension, diabetes.
Kaempferia galamga, alias: husky ginger, three a kind of apples, mountain are peppery, perennial herb, be Zingiber kaempferia galanga platymiscium kaempferia galanga (
Kaempferia galanga Linn.) rhizome, kaempferia galamga volatile oil, Kaempferol are contained in kaempferia galamga.Anaesthetic name Cha Gan-loud, high-pitched sound,
For the rhizome of zingiberaceous plant kaempferia galamga Kaemp feria galangal L..Pharmacological property: acrid flavour, hardship, puckery, property is hot.Imitate it is light, sharp, dry,
It is rough.Major function: except Ba Dagan is conspicuous according to, middle benefit gas, stagnation resolvation.Cure mainly indigestion, stomach trouble, nausea, extravesated blood stasis of blood hematocele ruffian etc..
Prescription analysis: in this prescription, on the basis of previous embodiment, the Banlangen is substituted by kuh-seng, soil
Constuslactone is substituted by elecampane, and ursolic acid, crocin are substituted by cape jasmine, and Kaempferol is substituted by kaempferia galamga, this prescription purpose is
Under the premise of basic holding drug effect, drug cost is reduced, is replaced to drug dispensing with bulk pharmaceutical chemicals.
Preparation method analysis: first is that traditional anaesthetic preparation method the water-bindered pill is made in said medicine crushing by preparation method;System
Preparation Method two improves preparation method, by due to the dissolubility for the effective component that effect is played in prescription it is different, according to
Characteristic is first extracted the effective component of performance curative effect of agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves this five kinds of Chinese medicine,
There is the ingredient by the performance curative effect of remaining drug to be extracted, then again mix the two, suitable dosage form-ball is made
Agent.By this preparation method, the submember for not playing main function in prescription is eliminated, the performance in prescription has been refined
The ingredient of main function, specifies active component, reduces taking dose, facilitates patients, thus from another point of view indirectly
Enhance the therapeutic effect of drug, expand therapeutic domain, because of anaesthetic flavour of a drug, medication dose is big, cannot adhere to taking and
It refuses to take medicine, therapeutic effect reduction, therapeutic domain is caused to be substantially reduced;Preparation method three is on the basis of preparation method two to medicine
The active component of object has carried out further refining, and agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves five kinds of Chinese medicine are dissolved in petroleum ether
Invalid components reject, keep effective component more accurate, medication dose can further decrease, and also eliminate invalid components to trouble
Other ill-effects of person.
Experimental example brief introduction:
Since 2010, on the basis of not finding toxic side effect by toxicological experiment, a large amount of clinic trial is carried out, has been taken
Obtained satisfied curative effect.Experimental conditions are as follows:
Diagnostic criteria: " diagnostic criteria of bronchial asthma " (the China's knot formulated referring to Chinese Medical Association's respirology meeting branch
Core and breathing magazine, 2003,26(3): 132) and " Mongolian medicine's Illnesses Diagnoses criterion of therapeutical effect " (Beijing: Nationalities Press, 2007:
420-421).
Criterion of therapeutical effect: referring to the curative effect mark for the bronchial asthma that Chinese Medical Association's respirology meeting branch's asthma group is formulated
Standard is drafted.Clinic control: patient's asthma symptoms complete incidence graph, and 80% or more of the reachable predicted value of FEVI (respiratory capacity), or exhale
15% or less gas peak flow velocity diurnal fluctuation;It is effective: patient's asthma attack with it is substantially reduced before treatment, and FEVI is in predicted value
Between 60% -79% or End--tidal PCO_2 diurnal fluctuation is between 15% -20%;Improve: patient's asthma symptoms mitigate, but FEVI
Predicted value 60% hereinafter, or End--tidal PCO_2 diurnal fluctuation 20% or more;It is invalid: the clinical symptoms and FEVI of patient, or
The equal no significant improvement or aggravation of climacteric flow velocity.
Since 2010, clinic aspiration asthmatic patient 118, male 58, women 60, the age is sick at 26-70 years old
Journey 1-10 years, three groups, under the same terms are randomly divided into, drug made from three kinds of preparation methods of this prescription is taken respectively, takes preparation
The instructions of taking of drug made from method one: 2-3g(amounts containing main ingredient)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of 15 days,
The good medicine of disease stops;Take the instructions of taking of drug made from preparation method two: 1.0-1.5g(amounts containing main ingredient)/time, 3 times a day, clothes
With 3 courses for the treatment of, a course for the treatment of 15 days, the good medicine of disease stops;Take the instructions of taking of drug made from preparation method two: 1.0-1.5g(contain
Main ingredient amount)/time, it 3 times a day, takes 3 course for the treatment of, a course for the treatment of 15 days, the good medicine of disease stops;Experimental result is shown in the following table 5:
Clinic control rate=[clinic control (example)/sum (example)] * 100%
Obvious effective rate=[effective (example)/total (example)] * 100%
Improvement rate=[improve (example)/total (example)] * 100%
Total effective rate=[total (example)-is invalid (example)] * 100%
By table as it can be seen that the clinic control rate of the present embodiment, total effective rate differ 1-4 percentages not as good as the 4th kind of embodiment
Point, under the premise of saving raw material, be using the method that bulk pharmaceutical chemicals are replaced to drug dispensing it is feasible, improve cost performance.
The above-mentioned patient of follow-up 1 year, without any toxicity, more after recidivist 1 people, caused by enviromental allergen stimulation.
Claims (10)
1. a kind of anaesthetic for treating asthma, it is characterised in that: the anaesthetic includes the bulk pharmaceutical chemicals of following parts by weight: oxtongue 10-
15 parts, 0.5-0.7 part of Banlangen, 0.06-0.08 part of alantolactone, 0.5-0.7 part of ursolic acid, crocin 1-2
Part, 0.05-0.07 part of Kaempferol.
2. a kind of anaesthetic for treating asthma according to claim 1, it is characterised in that: the raw material medicaments in part by weight adds
Enter: 5-7 parts of fructus choerospondiatis, 5-7 parts of falsespiraea tree bark, 9-11 parts of Inula britannica chinensis, 5-7 parts of myrobalan.
3. a kind of anaesthetic for treating asthma according to claim 2, it is characterised in that: the raw material medicaments in part by weight adds
Enter: 5-7 parts of Radix picrorrhizae, 5-7 parts of common bombax flower, 9-11 parts of nutmeg, 9-11 parts, 6-8 parts of Fructus meliae toosendan of vomiting nut (system).
4. a kind of anaesthetic for treating asthma according to claim 3, it is characterised in that: the raw material medicaments in part by weight adds
Enter: 12-13 parts of agalloch eaglewood, 12-13 parts of dalbergia wood, 12-13 parts of mountain agalloch eaglewood, 9-11 parts of costus root, 9-11 parts of cloves.
5. a kind of conspicuous anaesthetic according to analgesic of relievining asthma of suppression described in any one according to claim 1-4, it is characterised in that: institute
0.5-0.7 part of the Banlangen stated is substituted by 5-7 parts of kuh-seng, and 0.06-0.08 part of alantolactone is replaced by 5-6 parts of elecampane
Generation, 0.5-0.7 part of ursolic acid, 1-2 parts of crocin are substituted by 38-42 parts of cape jasmines, and 0.05-0.07 part of Kaempferol by 5-7
Part kaempferia galamga substitution.
6. a kind of preparation method for the anaesthetic for treating asthma, feature described in any one according to claim 1-4 exist
In: the bulk pharmaceutical chemicals be crushed into 80 meshes, mix, powder or water-bindered pill agent or tablet is made.
7. a kind of preparation method of anaesthetic for treating asthma according to claim 5, it is characterised in that: by the bulk pharmaceutical chemicals
It crushed 80 meshes, mix, powder or water-bindered pill agent or tablet is made.
8. a kind of preparation method of anaesthetic for treating asthma according to claim 4, it is characterised in that: will be in bulk pharmaceutical chemicals
Agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds distilled water, impregnates 30min, is placed in volatile oil extractor
In, add water, past medicinal material liquid level 3-4cm, heating water bath collects the volatile oil that above-mentioned raw materials medicine extracts, and it is spare, then
Remaining drug be crushed into 80 meshes, 75% alcohol reflux is added to extract 1-2 hours, filtrate is collected in filtering, and concentration must be concentrated
Object uniformly mixes with above-mentioned volatile oil, adds auxiliary material, pill is made.
9. a kind of preparation method of anaesthetic for treating asthma according to claim 5, it is characterised in that: will be in bulk pharmaceutical chemicals
Agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds distilled water, impregnates 30min, is placed in volatile oil extractor
In, add water, past medicinal material liquid level 3-4cm, heating water bath collects the volatile oil that above-mentioned raw materials medicine extracts, and it is spare, then
Remaining drug be crushed into 80 meshes, 75% alcohol reflux is added to extract 1-2 hours, filtrate is collected in filtering, and concentration must be concentrated
Object uniformly mixes with above-mentioned volatile oil, adds auxiliary material, pill is made.
10. a kind of preparation method of anaesthetic for treating asthma according to claim 5, it is characterised in that: will be in bulk pharmaceutical chemicals
Agalloch eaglewood, dalbergia wood, mountain agalloch eaglewood, costus root, cloves is ground into coarse powder, adds distilled water, impregnates 30min, is placed in volatile oil extractor
In, add water, past medicinal material liquid level 3-4cm, heating water bath collects the volatile oil that above-mentioned raw materials medicine extracts, and it is spare, then
Remaining drug be crushed into 80 meshes, first with being washed to it under the conditions of 70 DEG C of petroleum ether, filter, discard filtrate, filter residue adds
75% alcohol reflux extracts 1-2 hours, filtering, collects filtrate, and concentration obtains concentrate, uniformly mixes, add with above-mentioned volatile oil
Pill is made in auxiliary material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811575416.0A CN109432165A (en) | 2018-12-22 | 2018-12-22 | A kind of anaesthetic and preparation method thereof for treating asthma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811575416.0A CN109432165A (en) | 2018-12-22 | 2018-12-22 | A kind of anaesthetic and preparation method thereof for treating asthma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109432165A true CN109432165A (en) | 2019-03-08 |
Family
ID=65534990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811575416.0A Pending CN109432165A (en) | 2018-12-22 | 2018-12-22 | A kind of anaesthetic and preparation method thereof for treating asthma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109432165A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111820300A (en) * | 2019-04-15 | 2020-10-27 | 内蒙古中传实业有限公司 | Mongolian goldthread tea and preparation method thereof |
FR3104024A1 (en) * | 2019-12-09 | 2021-06-11 | Christian STRUNDEN | ANTI-ALLERGIC COMPOSITIONS BASED ON SAFFRON AND FLAVONOID |
KR102367536B1 (en) * | 2020-10-06 | 2022-02-25 | 동의대학교 산학협력단 | Functional composition for anti-pollution and anti-wrinkle with skin aging improvement effect containing picris hieracioides var. koreana leaf extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1374114A (en) * | 2002-02-27 | 2002-10-16 | 内蒙古锡林郭勒盟蒙医研究所 | New prepn process of Lideri as one traditional Mongoliam medicine |
CN106728455A (en) * | 2017-02-20 | 2017-05-31 | 陶乌日娜 | A kind of externally used Mongolian medicine composition for treating dermatitis, eczema and preparation method thereof |
-
2018
- 2018-12-22 CN CN201811575416.0A patent/CN109432165A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1374114A (en) * | 2002-02-27 | 2002-10-16 | 内蒙古锡林郭勒盟蒙医研究所 | New prepn process of Lideri as one traditional Mongoliam medicine |
CN106728455A (en) * | 2017-02-20 | 2017-05-31 | 陶乌日娜 | A kind of externally used Mongolian medicine composition for treating dermatitis, eczema and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
奥•乌力吉,等: "《传统蒙药与方剂》", 31 December 2013, 赤峰:内蒙古科学技术出版社 * |
柯铭清: "《中药有效成分理化与药理特性》", 31 October 1982, 湖南科学技术出版社 * |
王焕云等: "薄层扫描法测定蒙药查干-汤中土木香内酯的含量 ", 《中国民族医药杂志》 * |
蒙医学编辑委员会: "《中国医学百科全书 蒙医学》", 31 December 1992, 上海科学技术出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111820300A (en) * | 2019-04-15 | 2020-10-27 | 内蒙古中传实业有限公司 | Mongolian goldthread tea and preparation method thereof |
FR3104024A1 (en) * | 2019-12-09 | 2021-06-11 | Christian STRUNDEN | ANTI-ALLERGIC COMPOSITIONS BASED ON SAFFRON AND FLAVONOID |
KR102367536B1 (en) * | 2020-10-06 | 2022-02-25 | 동의대학교 산학협력단 | Functional composition for anti-pollution and anti-wrinkle with skin aging improvement effect containing picris hieracioides var. koreana leaf extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Wyk et al. | Medicinal plants of the world | |
Koul et al. | Genus Psoralea: A review of the traditional and modern uses, phytochemistry and pharmacology | |
Rodriguez-Fragoso et al. | Risks and benefits of commonly used herbal medicines in Mexico | |
KR101445010B1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof | |
CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
Kamruzzaman et al. | A review on ethnomedicinal, phytochemical and pharmacological properties of Phyllanthus niruri | |
Roeder et al. | Pyrrolizidine alkaloids in medicinal plants of Mongolia, Nepal and Tibet | |
CN105939721A (en) | Herbal combinations for treatment of a skin condition | |
CN114699467B (en) | Traditional Chinese medicine for clearing lung and reducing fever and application thereof | |
CN109432165A (en) | A kind of anaesthetic and preparation method thereof for treating asthma | |
CN102698137A (en) | Composition with blood pressure reducing function and preparation method of same | |
Khare et al. | The modern Ayurveda: milestones beyond the classical age | |
Öztürk et al. | Hepatoprotective activity of Hypericum perforatum L. alcoholic extract in rodents | |
Kumar et al. | Indian medicinal plants used for treatment of rheumatoid arthritis | |
Islam et al. | A review on medicinal uses of different plants of Euphorbiaceae family | |
CN104306659B (en) | A kind of Chinese medicine composition for treating diabetes B | |
Li | Chinese herbal medicine | |
CN102886014B (en) | Anticancer drug capable of clearing blood and diminishing inflammation | |
CN101584759B (en) | Pharmaceutical composition with pure plant origin and application thereof | |
CN108324816A (en) | A kind of anaesthetic and preparation method thereof for treating rheumatic arthritis | |
CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
CN104873778A (en) | Otitis media treatment drops and preparation method | |
CN109512901A (en) | Radix Wikstroemae extract and its preparing the application in antalgic and inflammation relieving drug | |
KR102223717B1 (en) | The crude drugs composition of decreation or treating chronic obstructive pulmonary disease, phamacopuncture injection of oriental medicinie containing the same and Injection containing the same | |
CN107233486A (en) | It is a kind of to treat old salt lemon composition of pharyngitis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |